US 11,883,479 B2
Method for treating cervical cancer
Young Chul Sung, Seoul (KR); Jung Won Woo, Seoul (KR); Jong Sup Park, Seoul (KR); and Jin Won Youn, Yongin-si (KR)
Assigned to GENEXINE, INC., Seongnam-si (KR); and MSD International GmbH, Lucerne (CH)
Filed by GENEXINE, INC., Seongnam-si (KR); and MSD International GmbH, Lucerne (CH)
Filed on Apr. 26, 2021, as Appl. No. 17/240,224.
Claims priority of provisional application 63/015,076, filed on Apr. 24, 2020.
Prior Publication US 2021/0330779 A1, Oct. 28, 2021
Int. Cl. A61P 35/00 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 39/39 (2006.01); C07K 14/00 (2006.01); C07K 16/28 (2006.01); C12N 7/00 (2006.01)
CPC A61K 39/12 (2013.01) [C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C12N 7/00 (2013.01); A61K 2039/507 (2013.01); A61K 2039/53 (2013.01); C12N 2710/20034 (2013.01)] 21 Claims
 
1. A method for treating human papillomavirus (HPV)-induced cancer in a subject in need thereof, comprising administering an HPV vaccine and a checkpoint inhibitor agent to the subject, over a common period of time, for generating a therapeutic effect greater than either the HPV vaccine or checkpoint inhibitor alone when used as monotherapy.